StockData

Cue Biopharma vs Xencor

CUE and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CUE and XNCR compare

Xencor is the larger company, worth 125 times as much as Cue Biopharma ($2.6B against $20.6M).

Cue Biopharma grew revenue faster over the last twelve months (354% versus −28.6% for Xencor).

Xencor keeps more of each dollar of sales as profit, with a net margin of −156% compared with −436% at Cue Biopharma.

Cue Biopharma scores higher on the StockData Score (8 against 5 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCUEXNCR
Size and price
Market cap$20.6M$2.6B
Share price$2.83$34.50
Change, 1 year−85.0%131%
Change, 5 years−99.3%−2.7%
Beta (5Y)–−0.05
Employees29260
StockData Score
Total score8 (better)5
Valuation score00
Growth score2 (better)1
Performance score11
Health score5 (better)3
Dividend score00
Valuation
P/S0.5× (better)24.4×
P/B8.9×5.1× (better)
FCF yield−244%−8.1% (better)
Fair value–$11.73
Margin of safety–−194%
Growth
Revenue growth (TTM)354% (better)−28.6%
Revenue growth, 5Y average54.2% (better)0.47%
Profitability
Operating margin−262%−206% (better)
Net margin−436%−156% (better)
FCF margin−133% (better)−198%
Return on equity−1603%−29.1% (better)
Return on invested capital–−26.6%
Financial health
Debt / equity0.000.21 (better)
Interest coverage–−8.0×
Current ratio1.256.39 (better)
Altman Z-score−32.755.01 (better)
Piotroski F-score5 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions22.6%113%
Held by insiders17.4%1.6%
Insider net buying, 12 months−$2.3M (better)−$7.5M
Short interest, % of float14.4%17.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.